DNA Healthlink, Inc. (2005 - Present)
President
My consulting firm, DNA Healthlink, Inc., specializes in emerging biopharmaceutical and technology
companies. I provide a range of consulting services to early-stage and turn-around biopharmaceutical
companies including new business and regulatory strategy, hands-on operations management, due
diligence, and facilitation of M&A and licensing deals. Through DNA Healthlink, I currently oversee
the strategic planning, business development and M&A, and clinical development programs at two
publically-traded companies, RespireRx Pharmaceuticals and Generex Biotechnology.
Generex Biotechnology (OTCQB:GNBT) [b ](January 1, 2017 – Present)[/b]
Executive Vice President, Research & Development
Generex Biotechnology, Inc., is an integrated life science holding company with end-to-end
healthcare solutions for patient centric care from rapid diagnosis through delivery of personalized
therapies. Generex has been a publicly traded company for over 20 years (Incorporated in 1997) and
continues to be traded on the OTCQB (GNBT). As part of the company’s executive team, we have
completed a strategic reorganization and operational transformation of the entire corporate structure,
including an M&A strategy that has enabled the company to transform from and research driven
biotech to a revenue generating healthcare company.
In the effort to transform and rebuild the company, I lead the technology search and
acquisition process and coordinate activities for global licensing and business development,
while overseeing the clinical development efforts across the organization to advance the
mission of Generex. Additionally, I have worked with the CEO to define the corporate strategy
and communicate to shareholders through public relations efforts.
BDM&A
Olaregen Therapeutix – CTP for wound care
Regentys Corporation – de novo 510k for ulcerative colitis
NuGenHealth – SaaS system for remote patient monitoring
DME-IQ – SaaS system for orthopedic inventory management & billing
ALTuCELL – Microencapsulation & cellular therapy company
Reorganization of Antigen Express to NuGenerex Immuno-Oncology for public spin out
NuGenerex Immuno-Oncology (NGIO)
Executive Vice President, Research & Development (January 1, 2017 – Present)
Chief Operating Officer (2012 – 2014)
NuGenerex Immuno-Oncology (formerly Antigen Express) ws a subsidiary of Generex Biotechnology
with a patented immune system modulation technology called Ii-Key. A primary focus of my work with
NGIO has been the spin out of the subsidiary as a separate public company, which has been
accomplished in preparation for a listing on a major exchange. To accomplish the spin out, we signed
a research agreement with Merck to conduct a Phase II trial of AE37 (Ii-Key-HER2/neu) in
combination with Keytruda for the treatment of triple negative breast cancer, which is ongoing.
From 2012 to 2014, I was hired to rescue the AE37 breast cancer clinical development program,
Richard D. Purcell
richard.purcell@dnahealthlink.com 732-492-1797
which was successfully completed in 2016. Since 2017, I have been part of the executive
management team charged with executing a turnaround, effect a corporate reorganization, and
initiate a pharma partnering effort. I currently oversee the research and development, and corporate
strategy for NGIO, which has been spun-out of Generex as a separate, publicly reporting company to
be listed on Nasdaq. NGIO has completed a Phase II study of its lead compound AE37
immunotherapeutic vaccine for the prevention of recurrent breast cancer, the company is currently
conducting a Phase II trial combining AE37 with Keytruda (Merck) for the treatment of triple negative
breast cancer. Additionally, are developing a COVID-19 vaccine with the Ii-Key immunomodulating
vaccine technology.
Patent Application
Multi-Targeting, Multi-Functional Selective Immune-Regulatory Ii-Key Peptide Vaccines For
Prophylaxis and Long-Term Protection Against SARS-CoV-2 Infection and COVID-19 Disease
Without Antibody Dependent Enhancement (ADE), and Related Compositions and Methods for
the Design, Construction, Formulation and Use of Anti-SARS-CoV-2 Ii-Key Hybrid Peptide
Vaccines
63/130,822. 27 December 2020
https://img1.wsimg.com/blobby/go/45bdd8f4-0e4...0478595666
President
My consulting firm, DNA Healthlink, Inc., specializes in emerging biopharmaceutical and technology
companies. I provide a range of consulting services to early-stage and turn-around biopharmaceutical
companies including new business and regulatory strategy, hands-on operations management, due
diligence, and facilitation of M&A and licensing deals. Through DNA Healthlink, I currently oversee
the strategic planning, business development and M&A, and clinical development programs at two
publically-traded companies, RespireRx Pharmaceuticals and Generex Biotechnology.
Generex Biotechnology (OTCQB:GNBT) [b ](January 1, 2017 – Present)[/b]
Executive Vice President, Research & Development
Generex Biotechnology, Inc., is an integrated life science holding company with end-to-end
healthcare solutions for patient centric care from rapid diagnosis through delivery of personalized
therapies. Generex has been a publicly traded company for over 20 years (Incorporated in 1997) and
continues to be traded on the OTCQB (GNBT). As part of the company’s executive team, we have
completed a strategic reorganization and operational transformation of the entire corporate structure,
including an M&A strategy that has enabled the company to transform from and research driven
biotech to a revenue generating healthcare company.
In the effort to transform and rebuild the company, I lead the technology search and
acquisition process and coordinate activities for global licensing and business development,
while overseeing the clinical development efforts across the organization to advance the
mission of Generex. Additionally, I have worked with the CEO to define the corporate strategy
and communicate to shareholders through public relations efforts.
BDM&A
Olaregen Therapeutix – CTP for wound care
Regentys Corporation – de novo 510k for ulcerative colitis
NuGenHealth – SaaS system for remote patient monitoring
DME-IQ – SaaS system for orthopedic inventory management & billing
ALTuCELL – Microencapsulation & cellular therapy company
Reorganization of Antigen Express to NuGenerex Immuno-Oncology for public spin out
NuGenerex Immuno-Oncology (NGIO)
Executive Vice President, Research & Development (January 1, 2017 – Present)
Chief Operating Officer (2012 – 2014)
NuGenerex Immuno-Oncology (formerly Antigen Express) ws a subsidiary of Generex Biotechnology
with a patented immune system modulation technology called Ii-Key. A primary focus of my work with
NGIO has been the spin out of the subsidiary as a separate public company, which has been
accomplished in preparation for a listing on a major exchange. To accomplish the spin out, we signed
a research agreement with Merck to conduct a Phase II trial of AE37 (Ii-Key-HER2/neu) in
combination with Keytruda for the treatment of triple negative breast cancer, which is ongoing.
From 2012 to 2014, I was hired to rescue the AE37 breast cancer clinical development program,
Richard D. Purcell
richard.purcell@dnahealthlink.com 732-492-1797
which was successfully completed in 2016. Since 2017, I have been part of the executive
management team charged with executing a turnaround, effect a corporate reorganization, and
initiate a pharma partnering effort. I currently oversee the research and development, and corporate
strategy for NGIO, which has been spun-out of Generex as a separate, publicly reporting company to
be listed on Nasdaq. NGIO has completed a Phase II study of its lead compound AE37
immunotherapeutic vaccine for the prevention of recurrent breast cancer, the company is currently
conducting a Phase II trial combining AE37 with Keytruda (Merck) for the treatment of triple negative
breast cancer. Additionally, are developing a COVID-19 vaccine with the Ii-Key immunomodulating
vaccine technology.
Patent Application
Multi-Targeting, Multi-Functional Selective Immune-Regulatory Ii-Key Peptide Vaccines For
Prophylaxis and Long-Term Protection Against SARS-CoV-2 Infection and COVID-19 Disease
Without Antibody Dependent Enhancement (ADE), and Related Compositions and Methods for
the Design, Construction, Formulation and Use of Anti-SARS-CoV-2 Ii-Key Hybrid Peptide
Vaccines
63/130,822. 27 December 2020
https://img1.wsimg.com/blobby/go/45bdd8f4-0e4...0478595666
1
